Fed. Circ. Upholds Ruling For Aventis Over ALS Drug
The U.S. Court of Appeals for the Federal Circuit ruled Friday that the U.S. District Court for the District of Delaware correctly determined last year that Aventis's drug Rilutek was not anticipated by an earlier patent, as Impax had argued.
The dispute was over a key patent for...
To view the full article, register now.